January 02, 2026

Nitrous Oxide Shows Brief, Rapid Antidepressant Effects

Early trials reveal short-lived effects

Conexiant

January 02, 2026

New Trial Tests Gabapentin As Treatment for Mucositis, Replacing Opioids

A new trial available at Roswell Park Comprehensive Cancer Center, organized by the Alliance for Clinical Trials in Oncology Foundation, is looking to determine the efficacy of using gabapentin for pain mitigation.

Roswell Park Comprehensive Cancer Center

January 02, 2026

Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma

As reported in The Lancet Oncology by Qin et al, the final analysis of the phase III CARES-310 trial has shown superior overall survival with camrelizumab plus rivoceranib vs sorafenib in the first-li...

The ASCO Post

January 02, 2026

Curative Treatment After First-Line Immunotherapy Improves Survival in HCC

Curative treatment—resection, transplantation, and/or local ablation—following first-line immunotherapy is infrequently received, but when it was utilized, it significantly improved overall survival o...

The ASCO Post

January 02, 2026

Perioperative Camrelizumab Plus Rivoceranib vs Surgery Alone in Hepatocellular Carcinoma

In a Chinese phase II/III trial (CARES-009) reported in The Lancet, Wang et al found that the addition of perioperative camrelizumab (PD-1 inhibitor) and rivoceranib (VEGFR2 inhibitor) to surgical res...

The ASCO Post

January 02, 2026

Risk of Liver Cancer With Oral Contraceptive Use

In a UK population-based study reported in The Lancet Oncology, Watling et al examined the relationship between ever use vs never use of oral contraceptives and the risk of liver cancer. Some findings...

The ASCO Post

January 02, 2026

Surgery vs Ablation in Small Hepatocellular Carcinoma

In two Japanese studies (SURF-RCT and SURF-Cohort) reported in the Journal of Clinical Oncology, Kawaguchi et al compared the outcomes of surgery vs radiofrequency ablation in patients with small hepa...

The ASCO Post

January 02, 2026

The Canary in the Vaccine Schedule

Cohort study reveals declining MMR coverage despite consistent health care access, with early vaccination patterns emerging as strongest indicator of timely immunization.

Conexiant

January 02, 2026

Benefits Mount for TROP2-Directed Antibody-Drug Conjugates in Triple-Negative Breast Cancer

Two randomized phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2025 bolster support for the use of antibody–drug conjugates—in particular, trophoblast cell surf...

The ASCO Post